GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price traded down 6.7% on Wednesday . The stock traded as low as $6.95 and last traded at $7.00. 91,514 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 77,875 shares. The stock had previously closed at $7.50.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, November 18th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Wednesday, November 20th. Finally, JMP Securities reissued a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.
Read Our Latest Stock Analysis on GHRS
GH Research Stock Performance
The firm's 50 day moving average price is $8.33 and its two-hundred day moving average price is $9.34. The firm has a market cap of $411.54 million, a PE ratio of -10.01 and a beta of 0.78.
Institutional Investors Weigh In On GH Research
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. raised its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is currently owned by institutional investors.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Recommended Stories
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
